Prognostic factors in patients with advanced cholangiocarcinoma: Role of surgery, chemotherapy and body mass index

Table 3 Association between clinical variables and survival in patients with cholangiocarcinoma

Variable (n)	Median survival (mo)	P (Univariate)
Age
< 50 (11)	10.23 (1.87-18.6)	0.410
≥ 50 (44)	9.17 (3.9-14.4)
Gender
Male (33)	9.17 (3.8-14.5)	0.386
Female (22)	9.9 (0.4-19.4)
Bilirubin
< 10 (27)	9.9 (3.1-16.7)	0.012
≥ 10 (17)	2.87 (1.2-4.5)
BMI
< 25 (18)	13.0 (8.5-17.6)	0.412
25-30 (16)	7.0 (3.2-10.8)
≥ 30 (18)	4.0 (0.5-7.6)
Surgery
Yes (21)	10.23 (4.82-15.64)	0.038
No (34)	8.7 (1.8-15.6)
Type of surgery
Whipple (6)	16.6 (0.0-39.4)	0.988
Hepatic lobectomy (6)	10.2 (3.9-16.6)
Bile duct excision (9)	14.3 (8.5-20.1)
Metastasis
Yes (19)	7.07 (0.0-15.83)	0.256
No (36)	9.09 (6.05-13.75)
Stenting
Yes (24)	9.9 (0.45-19.35)	0.930
No (32)	9.16 (4.6-13.7)
Chemotherapy
Yes (14)	16.96 (11.5-22.4)	0.038
No (41)	6.2 (0-12.9)
Chemotherapy in unresected patients
Yes (8)	17 (12.76-21.18)	0.001
No (25)	3.5 (1.12-5.8)